Literature DB >> 6176183

Alpha interferon administration to infants with congenital rubella.

A M Arvin, N J Schmidt, K Cantell, T C Merigan.   

Abstract

Three infants with congenital rubella syndrome were given human leukocyte (alpha) interferon at doses of 2 x 10(5) to 7 X 10(5) U/kg per day for 10 days. A transient decrease in pharyngeal virus excretion was observed with treatment. No significant side effects were associated with the administration of human leukocyte interferon to these infants.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6176183      PMCID： PMC181869          DOI： 10.1128/AAC.21.2.259

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Administration of interferon to an infant with congenital rubella syndrome involving persistent viremia and cutaneous vasculitis.

Authors:  A Larsson; M Forsgren; S Hård af Segerstad; H Strander; K Cantell
Journal:  Acta Paediatr Scand       Date:  1976-01

2.  Clinical manifestations of postnatal and congenital rubella.

Authors:  L Z Cooper; S Krugman
Journal:  Arch Ophthalmol       Date:  1967-04

3.  Interferon in congenital rubella: response to live attenuated measles vaccine.

Authors:  J Desmyter; W E Rawls; J L Melnick; M D Yow; F F Barrett
Journal:  J Immunol       Date:  1967-10       Impact factor: 5.422

4.  Inhibition of rubella virus-specific RNA synthesis by interferon.

Authors:  K T Wong; W S Robinson; T C Merigan
Journal:  Proc Soc Exp Biol Med       Date:  1971-02

Review 5.  Congenital rubella.

Authors:  J A Dudgeon
Journal:  J Pediatr       Date:  1975-12       Impact factor: 4.406

6.  Comparison of immunofluorescence and immunoperoxidase staining for identification of rubella virus isolates.

Authors:  N J Schmidt; J Dennis; E H Lennette
Journal:  J Clin Microbiol       Date:  1978-06       Impact factor: 5.948
  6 in total
  4 in total

Review 1.  Varicella zoster virus immune evasion strategies.

Authors:  Allison Abendroth; Paul R Kinchington; Barry Slobedman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

2.  Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency.

Authors:  Ludmila Perelygina; Timo Hautala; Mikko Seppänen; Adebola Adebayo; Kathleen E Sullivan; Joseph Icenogle
Journal:  Antiviral Res       Date:  2017-09-30       Impact factor: 5.970

3.  Chapter 3 Antiviral drugs: general considerations.

Authors: 
Journal:  Perspect Med Virol       Date:  2008-05-29

4.  Interferons and viral infections.

Authors:  P G Higgins
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.